Latest CompoZr Stories

MADISON, Wis., June 5, 2013 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it has expanded its MyCell® Products line, offering access to a number of human disease models and licensing key genetic engineering patents from Life Technologies and Sigma-Aldrich. CDI's MyCell Products include custom cell products manufactured using induced pluripotent stem cell (iPSC) technology to make stem cells or differentiated cells from any individual, including those with...

ST LOUIS, June 4, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC(®) Commercial (www.safcglobal.com), its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN(®), their off-the-shelf cell line production platform. The contracts feature the CHOZN(®) Platform system as a key component of each customer's global biotherapeutic...

ST. LOUIS, Feb. 12, 2013 /PRNewswire/ -- Sigma-Aldrich(®) Corporation (NASDAQ: SIAL), a leading Life Science and High Technology Company, announced that Sigma(®) Life Science, its innovative biological products and services business, signed an agreement to distribute worldwide Olink Bioscience's Duolink(®) In Situ products, which present a new disruptive method for imaging and measuring protein-protein interactions in unmodified cells. The Duolink In Situ products work in tandem...

ST. LOUIS, Nov. 20, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) announced that Sigma Life Science, its innovative biological products and services business, today launched its CompoZr® Transporter Knockout human cell lines in a consumable, assay-ready plate format. The efflux transporter knockout cell lines allow precise identification of individual drug-transporter interactions, a critical component for understanding the safety and efficacy characteristics of...

ST. LOUIS, April 26, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, launched the first kit to precisely and efficiently integrate transgenes into the rat genome. The highly affordable CompoZr® Targeted Integration Kit - Rosa26 integrates transgenes into the conserved, ubiquitously expressed Rosa26 safe harbor locus in the rat genome. The Rosa26 locus is widely...

ST. LOUIS, April 19, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma® Life Science, extended CompoZr® Zinc Finger Nuclease (ZFN) technology to achieve the first tissue-specific conditional knockout of an endogenous gene in rats. For two decades this approach for generating sophisticated disease models could be performed only in mice. Rats, however, are preferred by drug...

ST. LOUIS, April 11, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), is launching the CHOZN® Platform system, a CHO (Chinese Hamster Ovary) cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs. The new platform consists of the cGMP-produced and tested CHOZN® ZFN...

ST. LOUIS, Jan. 31, 2012 /PRNewswire/ -- From: Rakesh Sachdev, President and CEO: Sigma-Aldrich Corporation (NASDAQ:SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments. BioReliance provides critical services that include...

ST. LOUIS, Oct. 27, 2011 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), is introducing a novel CHOZN® GS-/- Zinc Finger Nuclease (ZFN)-modified Chinese Hamster Ovary (CHO) cell line. Designed for use in the production of biopharmaceuticals, the new CHOZN GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO cell line proven to shorten...

ST. LOUIS, Aug. 3, 2011 /PRNewswire/ -- Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced a major breakthrough in the development of its proprietary CompoZr zinc finger nuclease (ZFN) technology with the release of more Knockout ZFNs covering the entire genomes of both mice and rats, while the pricing of products within the CompoZr ZFN portfolio by half. A new dedicated high-throughput manufacturing...